Literature DB >> 11264707

Murine model of chronic human asthma.

R K Kumar1, P S Foster.   

Abstract

Human asthma is associated with acute and chronic inflammation of the airway mucosa, accompanied by airway wall remodelling. Experimental models of acute allergic bronchopulmonary inflammation in mice are useful for investigation of immunological mechanisms and of cellular recruitment, but have significant limitations because they fail to reproduce a number of characteristic lesions of human asthma, while usually being associated with marked alveolitis. We have developed an improved murine model of asthma that exhibits almost all of the morphological and functional changes that typify the human disease, without any confounding alveolitis. This model has considerable potential for the investigation of pathogenetic mechanisms and potential treatments of chronic human asthma.

Entities:  

Mesh:

Year:  2001        PMID: 11264707     DOI: 10.1046/j.1440-1711.2001.00981.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  12 in total

1.  μ-chain-deficient mice possess B-1 cells and produce IgG and IgE, but not IgA, following systemic sensitization and inhalational challenge in a fungal asthma model.

Authors:  Sumit Ghosh; Scott A Hoselton; Jane M Schuh
Journal:  J Immunol       Date:  2012-06-25       Impact factor: 5.422

2.  Prevention and treatment of allergic inflammation by an Fcγ-Der f2 fusion protein in a murine model of dust mite-induced asthma.

Authors:  Li-hui Lin; Ping Zheng; John W M Yuen; Juan Wang; Juan Zhou; Cun-quan Kong; Xia Peng; Jia Li; Li Li
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

Review 3.  Usefulness and optimization of mouse models of allergic airway disease.

Authors:  Fred D Finkelman; Marsha Wills-Karp
Journal:  J Allergy Clin Immunol       Date:  2008-03       Impact factor: 10.793

4.  Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Authors:  Shailendra R Singh; Nikol Sullo; Maria Matteis; Giuseppe Spaziano; John McDonald; Ruth Saunders; Lucy Woodman; Konrad Urbanek; Antonella De Angelis; Raffaele De Palma; Rachid Berair; Mitesh Pancholi; Vijay Mistry; Francesco Rossi; Remo Guerrini; Girolamo Calò; Bruno D'Agostino; Christopher E Brightling; David G Lambert
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

5.  Transgenic expression of human S100A12 induces structural airway abnormalities and limited lung inflammation in a mouse model of allergic inflammation.

Authors:  M A Hofmann Bowman; A Heydemann; J Gawdzik; R A Shilling; B Camoretti-Mercado
Journal:  Clin Exp Allergy       Date:  2011-03-21       Impact factor: 5.018

6.  Influence of inhaled beclomethasone and montelukast on airway remodeling in mice.

Authors:  Rania R Abdel Aziz; Nadia Y Helaly; Khaled R Zalata; Nariman M Gameil
Journal:  Inflammopharmacology       Date:  2012-02-22       Impact factor: 4.473

7.  Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model.

Authors:  S Yamagata; K Tomita; R Sato; A Niwa; H Higashino; Y Tohda
Journal:  Clin Exp Immunol       Date:  2008-09-23       Impact factor: 4.330

8.  The contribution of L-selectin to airway hyperresponsiveness in chronic allergic airways disease.

Authors:  Simon G Royce; Melissa Lee; Mimi L K Tang
Journal:  J Asthma Allergy       Date:  2010-06-28

Review 9.  Understanding cellular mechanisms underlying airway epithelial repair: selecting the most appropriate animal models.

Authors:  B Yahaya
Journal:  ScientificWorldJournal       Date:  2012-09-23

10.  Time sequence of airway remodeling in a mouse model of chronic asthma: the relation with airway hyperresponsiveness.

Authors:  Seung Joon Kim; Chi Hong Kim; Joong Hyun Ahn; Myung Sook Kim; Seok Chan Kim; Sook Young Lee; Soon Seog Kwon; Young Kyoon Kim; Kwan Hyoung Kim; Hwa Sik Moon; Jeong Sup Song; Sung Hak Park
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.